^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MEK1 inhibitor

    Related drugs:
    Apply
    FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration (NCT07004075)
    Phase 3
    Shanghai Fosun Pharmaceutical Industrial Develo...
    Not yet recruiting
    Last update posted :
    06/04/2025
    Initiation :
    06/30/2025
    Primary completion :
    04/30/2027
    Completion :
    04/30/2029
    BRAF
    |
    carboplatin • temozolomide • Ivesa (firmonertinib) • Fumaining (luvometinib) • vindesine
    A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors (IMM1104-101) (NCT05585320)
    Phase 1/2
    Immuneering Corporation
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/31/2022
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    KRAS • HRAS • APC
    |
    KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)
    Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma (NCT03224767)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/05/2018
    Primary completion :
    10/01/2026
    Completion :
    08/01/2028
    CYP1A2
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib)
    Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer (ETCTN Study 10166) (NCT03600701)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    11/29/2018
    Primary completion :
    07/17/2025
    Completion :
    07/17/2025
    EGFR • KRAS • BRAF • ALK
    |
    KRAS wild-type • RAS wild-type
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib)
    XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma (NCT02721459)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    09/07/2016
    Primary completion :
    10/31/2019
    Completion :
    03/01/2025
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888
    Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers (NCT05691504)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/14/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    BRAF • BCL2L1
    |
    Cotellic (cobimetinib) • pelcitoclax (APG-1252)
    Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors (NCT06553365)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Not yet recruiting
    Last update posted :
    08/14/2024
    Initiation :
    08/15/2024
    Primary completion :
    07/31/2026
    Completion :
    07/31/2026
    NF2
    |
    Fumaining (luvometinib)
    Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (NCT06440850)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    11/30/2024
    Primary completion :
    11/30/2026
    Completion :
    11/30/2026
    BRAF
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib)
    Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (NCT03202316)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    08/11/2017
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PD-L1 • ER • PGR
    |
    HER-2 positive
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • eribulin mesylate
    Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NACHO COBI) (NCT04079179)
    Phase 2
    Carl Allen
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    04/19/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2029
    BRAF
    |
    Cotellic (cobimetinib)
    Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem) (NCT02902029)
    Phase 2
    University Hospital, Essen
    Completed
    Last update posted :
    05/23/2024
    Initiation :
    11/01/2016
    Primary completion :
    03/01/2024
    Completion :
    03/01/2024
    PD-1
    |
    BRAF mutation • BRAF V600
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)
    Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases (BEAT-MBM) (NCT03175432)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    06/15/2017
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    PD-L1 • BRAF • PD-1
    |
    PD-L1 expression • BRAF V600 • BRAF wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)